Vaccinia virus ts mutant-质粒载体-ATCC-DSM-CCUG-泰斯拓生物

你好,请登录   免费注册    |    收藏本站
联系电话: 0574-87917803
联系电话: 0574-87917803
Vaccinia virus ts mutant
Vaccinia virus ts mutant
规格:
货期:
编号:TS155581
品牌:Testobio
产品名称: Vaccinia virus ts mutant
商品货号: TS155581
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus ts mutant
Strain: IHD-W Dts80
Applications:
It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown).
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses.
Biosafety Level: 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Isolation:
This conditional lethal mutant, originally designated plaque isolate number 9021, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown). The non-permissive incubation temperature is 39.5oC.
Product Format: frozen
Storage Conditions: -70°C or colder
Comments:
This conditional lethal mutant, originally designated plaque isolate number 9021, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown). The non-permissive incubation temperature is 39.5oC.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses.
Effect on Host:
CPE: enlargement, plaques with rounding and eventual sloughing
Cytopathic effects in culture include enlargement and rounding of cells, followed by death and sloughing.
Growth Medium: ATCC® Medium 30-2002: Dulbeccos Modified Eagles Medium (DMEM)
Fetal Bovine Serum
Recommended Host:

Recommended Host: BSC-40 (ATCC CRL-2761)

Production host: BSC-40 (ATCC CRL-2761) Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2
Name of Depositor: S. Dales, R. Condit
References:

Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807

Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746

Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570

Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.

首页 > 产品中心 > 微生物培养 > 菌株 > null > Vaccinia virus ts mutant

Vaccinia virus ts mutant

  • 货号: TS155581
  • 好评
有货
  • 品牌 : TESTOBIO
产品名称: Vaccinia virus ts mutant
商品货号: TS155581
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus ts mutant
Strain: IHD-W Dts80
Applications:
It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown).
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses.
Biosafety Level: 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Isolation:
This conditional lethal mutant, originally designated plaque isolate number 9021, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown). The non-permissive incubation temperature is 39.5oC.
Product Format: frozen
Storage Conditions: -70°C or colder
Comments:
This conditional lethal mutant, originally designated plaque isolate number 9021, was isolated from the IHD-W strain of Vaccinia by S. Dales, selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. It was assigned to Dales EM category H,Q. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E(2-8) (exact location unknown). The non-permissive incubation temperature is 39.5oC.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses.
Effect on Host:
CPE: enlargement, plaques with rounding and eventual sloughing
Cytopathic effects in culture include enlargement and rounding of cells, followed by death and sloughing.
Growth Medium: ATCC® Medium 30-2002: Dulbeccos Modified Eagles Medium (DMEM)
Fetal Bovine Serum
Recommended Host:

Recommended Host: BSC-40 (ATCC CRL-2761)

Production host: BSC-40 (ATCC CRL-2761) Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2
Name of Depositor: S. Dales, R. Condit
References:

Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807

Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746

Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570

Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.

合作单位: